Trial Profile

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF 07062119 (Primary) ; Bevacizumab; Sasanlimab
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Pfizer

08 Feb 2024 Status changed from recruiting to discontinued.
25 Apr 2023 Planned End Date changed from 8 Feb 2025 to 12 Sep 2025.
25 Apr 2023 Planned primary completion date changed from 8 Feb 2025 to 12 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com